Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bert Vander Cruyssen

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Arthritis and Rheumatism|December 6, 2011
Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: comparison with controlled inflammatory arthritisRuth Wittoek, Bert Vander Cruyssen, Gust Verbruggen
Current Opinion in Rheumatology|May 22, 2013
Hip disease in ankylosing spondylitisBert Vander Cruyssen, Nathan Vastesaeger, Eduardo Collantes-Estévez
Annals of the Rheumatic Diseases|December 1, 2011
Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modificationGust Verbruggen, Ruth Wittoek, Bert Vander Cruyssen, et al.
Annals of the Rheumatic Diseases|December 2, 2009
Morbid anatomy of 'erosive osteoarthritis' of the interphalangeal finger joints: an optimised scoring system to monitor disease progression in affected jointsGust Verbruggen, Ruth Wittoek, Bert Vander Cruyssen, et al.
Arthritis Research & Therapy|May 13, 2010
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activityBert Vander Cruyssen, Patrick Durez, Rene Westhovens, et al.
Current Opinion in Rheumatology|April 7, 2007
Osteochondral repair in synovial jointsGust Verbruggen, Ruth Wittoek, Sara Groeneboer, et al.
Clinical Chemistry and Laboratory Medicine|October 31, 2019
Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritisLieve Van Hoovels, Bert Vander Cruyssen, Laura Bogaert, et al.
Arthritis Research & Therapy|September 14, 2010
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategiesBert Vander Cruyssen, Patrick Durez, Rene Westhovens, et al.
Plos One|November 29, 2016
A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise StudySophie De Mits, Jan Lenaerts, Bert Vander Cruyssen, et al.
Rheumatology International|September 27, 2008
Clinical observations programme in SpA: disease parameters, treatment options and practical management issuesDirk Elewaut, Filip Van den Bosch, Gust Verbruggen, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Arthritis and Rheumatism|December 6, 2011
Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: comparison with controlled inflammatory arthritisRuth Wittoek, Bert Vander Cruyssen, Gust Verbruggen
Current Opinion in Rheumatology|May 22, 2013
Hip disease in ankylosing spondylitisBert Vander Cruyssen, Nathan Vastesaeger, Eduardo Collantes-Estévez
Annals of the Rheumatic Diseases|December 1, 2011
Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modificationGust Verbruggen, Ruth Wittoek, Bert Vander Cruyssen, et al.
Annals of the Rheumatic Diseases|December 2, 2009
Morbid anatomy of 'erosive osteoarthritis' of the interphalangeal finger joints: an optimised scoring system to monitor disease progression in affected jointsGust Verbruggen, Ruth Wittoek, Bert Vander Cruyssen, et al.
Arthritis Research & Therapy|May 13, 2010
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activityBert Vander Cruyssen, Patrick Durez, Rene Westhovens, et al.
Current Opinion in Rheumatology|April 7, 2007
Osteochondral repair in synovial jointsGust Verbruggen, Ruth Wittoek, Sara Groeneboer, et al.
Clinical Chemistry and Laboratory Medicine|October 31, 2019
Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritisLieve Van Hoovels, Bert Vander Cruyssen, Laura Bogaert, et al.
Arthritis Research & Therapy|September 14, 2010
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategiesBert Vander Cruyssen, Patrick Durez, Rene Westhovens, et al.
Plos One|November 29, 2016
A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise StudySophie De Mits, Jan Lenaerts, Bert Vander Cruyssen, et al.
Rheumatology International|September 27, 2008
Clinical observations programme in SpA: disease parameters, treatment options and practical management issuesDirk Elewaut, Filip Van den Bosch, Gust Verbruggen, et al.
Pageof 4